| SPH4336 / Shanghai Pharma |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 08/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT05580588: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas |
|
|
| Recruiting | 2 | 33 | US | SPH4336 | Shanghai Pharma Biotherapeutics USA Inc. | Liposarcoma, Dedifferentiated | 03/25 | 03/25 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
NCT05905614: Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors |
|
|
| Completed | 1/2 | 29 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 10/23 | 10/23 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
ChiCTR2200057162: A phase Ⅰ, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH4336 monotherapy in patients with advanced solid tumors |
|
|
| Recruiting | 1 | 60 | | SPH4336 tablets ;SPH4336 tablets | West China Hospital of Sichuan University; Shanghai Pharmaceuticals Holding Co., Ltd., self-funded | solid tumors | | | | |
